Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands
Authors:
- Andrea Díaz-TejedorADAndrea Díaz-Tejedor
- Javier Rodríguez-UbrevaJRJavier Rodríguez-Ubreva
- Laura CiudadLCLaura Ciudad
- Mauro Lorenzo-MohamedMLMauro Lorenzo-Mohamed
- Marta González-RodríguezMGMarta González-Rodríguez
- Bárbara CastellanosBCBárbara Castellanos
- Janet Sotolongo-RaveloJSJanet Sotolongo-Ravelo
- Laura San-SegundoLSLaura San-Segundo
- Luis A. CorcheteLuis A. Corchete
- Lorena González-MéndezLGLorena González-Méndez
- Montserrat Martín-SánchezMMMontserrat Martín-Sánchez
- María-Victoria MateosMaría-Victoria Mateos
Open Access
- 26 April 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4718
Abstract
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients’ samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.Keywords
Funding Information
- Instituto de Salud Carlos III (PI18/01600, PI19/01384, PI21/01508, PI22/00877, PROYE20047GUTI, FRA16/003, FPU22/04397, INVES18043PAÍN)
- Fundación Científica Asociación Española Contra el Cáncer (PI18/01600, PI19/01384, PI21/01508, PI22/00877, PROYE20047GUTI, FRA16/003, FPU22/04397, INVES18043PAÍN)
- Fundación Ramón Areces (PI18/01600, PI19/01384, PI21/01508, PI22/00877, PROYE20047GUTI, FRA16/003, FPU22/04397, INVES18043PAÍN)
- Mundipharma Research Limited (PI18/01600, PI19/01384, PI21/01508, PI22/00877, PROYE20047GUTI, FRA16/003, FPU22/04397, INVES18043PAÍN)
- Purdue Pharma (PI18/01600, PI19/01384, PI21/01508, PI22/00877, PROYE20047GUTI, FRA16/003, FPU22/04397, INVES18043PAÍN)
- Consejería de Educación (Junta de Castilla y León) (PI18/01600, PI19/01384, PI21/01508, PI22/00877, PROYE20047GUTI, FRA16/003, FPU22/04397, INVES18043PAÍN)
- Ministerio de Ciencia, Innovación y Universidades (PI18/01600, PI19/01384, PI21/01508, PI22/00877, PROYE20047GUTI, FRA16/003, FPU22/04397, INVES18043PAÍN)
- Fundación Científica Asociación Española Contra el Cáncer (PI18/01600, PI19/01384, PI21/01508, PI22/00877, PROYE20047GUTI, FRA16/003, FPU22/04397, INVES18043PAÍN)
This publication has 49 references indexed in Scilit:
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialThe Lancet Oncology, 2021
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 studyThe Lancet, 2020
- Combining epigenetic and immune therapy to overcome cancer resistanceSeminars in Cancer Biology, 2019
- A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cellsMedical Oncology, 2019
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patientsCancer, 2019
- Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myelomaHematological Oncology, 2016
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumabLeukemia, 2015
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysisMolecular Immunology, 2005